Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1914 1
1930 1
1974 1
1980 1
1982 1
1983 2
1986 1
1990 2
1992 1
1993 1
1996 1
1998 6
1999 7
2000 7
2001 2
2002 5
2003 5
2004 2
2005 4
2006 7
2007 2
2008 2
2009 3
2010 6
2011 10
2012 10
2013 14
2014 9
2015 11
2016 8
2017 16
2018 29
2019 31
2020 38
2021 34
2022 37
2023 17
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25580725

312 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Villarino ME, et al. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.
Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Belknap R, et al. Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. Ann Intern Med. 2017. PMID: 29114781 Free PMC article. Clinical Trial.
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Sterling TR, et al. AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098. AIDS. 2016. PMID: 27243774 Free PMC article. Clinical Trial.
An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, Muñoz L, Gosce L, Rangaka MX, Francis M, Hack V, Kunst H, Abubakar I. Surey J, et al. BMC Infect Dis. 2021 Jan 21;21(1):90. doi: 10.1186/s12879-021-05766-9. BMC Infect Dis. 2021. PMID: 33478428 Free PMC article. Clinical Trial.
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Gordin F, et al. JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445. JAMA. 2000. PMID: 10732934 Clinical Trial.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. Swindells S, et al. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. N Engl J Med. 2019. PMID: 30865794 Free PMC article. Clinical Trial.
312 results